findmyKOL
Clinical trialNCT05275504UnknownPhase 1Interventional

Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

SponsorTransThera Sciences (Nanjing), Inc.Enrollment37B-Cell Malignancies
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Gabrail Cancer Center

    Canton, Ohio, United States

    Recruiting
  • the University of Texas Md Anderson Cancer Center (mdacc)

    Houston, Texas, United States

    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

TT-01488
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jun 2022
Primary completion
30 Sept 2022
Completion
30 Apr 2023
Last update posted
9 Jun 2022
Registered enrollment
37
Registry id
NCT05275504
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.